Simulation-augmented, Real-time Platform Adaptive Seamless Trials (SURPASS)
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (ARPA-H)
Contract Value
Not provided
Codes & Classification
Solicitation Number
ARPA-H-SOL-26-164
NAICS
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Classification Code
AN13
Additional Details
Documents4
The Advanced Research Projects Agency for Health (ARPA-H), operating under the Department of Health and Human Services and the National Institutes of Health, has issued a solicitation (ARPA-H-SOL-26-164) for its Simulation-augmented, Real-time Platform Adaptive Seamless Trials (SURPASS) program. This active opportunity seeks to advance the field of clinical research by supporting the development and implementation of innovative, adaptive trial platforms that leverage simulation and real-time data to enhance the efficiency, flexibility, and effectiveness of clinical trials.
The SURPASS program is designed to foster the creation of adaptive, seamless trial platforms that integrate simulation-augmented methodologies and real-time data analytics. The overarching goal is to transform traditional clinical trial paradigms, enabling more responsive, data-driven, and patient-centric research processes. By supporting the development of these advanced platforms, ARPA-H aims to accelerate the evaluation and deployment of new health interventions, ultimately improving patient outcomes and public health.
ARPA-H anticipates awarding multiple Other Transaction Agreements (OTAs) as a result of this solicitation, providing flexibility in the types of partnerships and deliverables that may be proposed. The scope of work is classified under NAICS code 541714, which pertains to Research and Development in Biotechnology (except Nanobiotechnology), and is further identified by Product Service Code AN13. This classification underscores the program’s focus on cutting-edge research and development activities within the biotechnology sector, specifically those that do not involve nanobiotechnology.
Key requirements and objectives for this procurement include the design, development, and demonstration of platform technologies that can support adaptive, seamless clinical trials. Offerors are expected to propose solutions that incorporate simulation tools and real-time data integration, with the aim of improving trial adaptability, reducing timelines, and enhancing the reliability of trial outcomes. Deliverables will likely include fully developed trial platforms, validated simulation models, and demonstrated capabilities for real-time data analysis and adaptive trial management.
The solicitation is open to a broad range of potential offerors, and there are no explicit set-aside requirements or special considerations noted in the provided information. Interested parties are encouraged to review the full solicitation and associated attachments, which are available via the official SAM.gov opportunity listing (Opportunity ID: c00c844955844519851bf8e53cda9f01). The procurement process includes an informational webinar scheduled for October 15, 2026, and a two-day Proposers’ Day event on November 6 and 9, 2026, providing prospective offerors with opportunities to engage with the program team and clarify requirements.
All inquiries regarding the SURPASS program should be directed to the SURPASS Team at [email protected]. The response deadline for this solicitation is November 30, 2026, at 22:11. Contractors with expertise in biotechnology research and development, particularly those with capabilities in simulation, real-time data analytics, and adaptive clinical trial design, are encouraged to consider this opportunity and assess alignment with their organizational strengths and strategic objectives.
For further details, including access to solicitation documents and attachments, interested parties should refer to the official notice on SAM.gov at https://sam.gov/opp/c00c844955844519851bf8e53cda9f01/view.